Orexo submits application to FDA for expanded label of ZUBSOLV
Orexo anticipates a potential approval of the expanded label during the third quarter 2015. The application for initiation of treatment is supported by the data from the ISTART
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.
"We are elated following the FDA’s approval of our IND application for MT-3724 and are eager to begin the next steps of our clinical journey with Veristat. Veristat
If granted, the FDA orphan drug designation will provide the company special development and commercial assistance, including a seven year period of marketing exclusivity. In September, the company
The Company will be presenting these findings today during a poster session at the American Neurological Association’s Annual Meeting in Baltimore, Maryland. Concert expects to initiate a Phase
Data were presented as a late-breaking abstract at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) meeting in Amsterdam. The results of this study,